 |
|
|
| |
Preclinical Assessments of a Cabotegravir Prodrug
Predicting Human Dosing Durations of >6 Months
|
| |
| |
AIDS 2024 Munich July 20-26
Mark Baker,1 William Proctor,2 Nick Falco,3 Liangfu Chen,3 Vicki Ironmonger,4 Sebastian Pearce,4 Andrew Weber,5
Max Lataillade6
1ViiV Healthcare, Munchenbuchsee, Switzerland; 2GSK, Waltham, MA, USA; 3GSK, Upper Providence, PA, USA; 4GSK, Stevenage, UK; 5ViiV Healthcare, Durham, NC, USA; 6ViiV Healthcare, Branford, CT, USA
|
| |
|
|
|
|
|
